12 active trials 5 recruiting 4 Phase 3 10 disease areas 1 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Trial sites expanded: 27 → 49 locations
Institut de Recherches Internationales ServierPhase 1/2 NCT05786924 Registry history of NCT05786924 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 4 | |
| Phase 1/2 | 4 | |
| Phase 3 | 4 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06465953 | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) | Recruiting | 2026-09-03 |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants… | Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, Not Recruiting | 2026-06-29 |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who… | Metastatic Colorectal Cancer | Active, Not Recruiting | 2025-12-22 |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma… | Grade 2 Glioma | Active, Not Recruiting | 2025-04-03 |
| Phase 1/2 | ||||
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Non-small Cell Lung Cancer | Recruiting | 2026-09-16 |
| NCT07227857 | A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related… | Epileptic Encephalopathy | Recruiting | 2026-08-11 |
| NCT06501625 | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in… | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Recruiting | 2026-05-11 |
| NCT06478212 | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | IDH1-mutant Glioma | Active, Not Recruiting | 2026-07-08 |
| Phase 1 | ||||
| NCT02074839 | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies… | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Recruiting | 2026-06-15 |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy… | Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, Not Recruiting | 2026-05-22 |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1… | Astrocytoma | Active, Not Recruiting | 2026-03-12 |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who… | Advanced Lymphoid Leukemia | Active, Not Recruiting | 2025-04-11 |
Leukemia (4) · Myelodysplastic Syndromes (MDS) (4) · Acute Myeloid Leukemia (AML) (3) · Glioma (3) · Colorectal Cancer (2) · Cholangiocarcinoma (1) · Epilepsy (1) · Lung Cancer (1) · Non-Small Cell Lung Cancer (NSCLC) (1) · Thyroid Cancer (1)